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Transcriptional repressionMatrixmetalloproteinase 14 (MMP-14) is amembrane-anchoredMMP crucial for tumorigenesis and aggressive-
ness, and is highly expressed in neuroblastoma (NB), the most common extracranial solid tumor in childhood.
Recent evidence shows the emerging roles of endogenous promoter-targeting microRNAs (miRNAs) in regulat-
ing gene transcription. However, the roles of miRNAs in the transcription of MMP-14 still remain largely
unknown. In this study, throughmining computational algorithm program and Argonaute-chromosome interac-
tion dataset, we identiﬁed one binding site of miRNA-584-5p (miR-584-5p) within theMMP-14 promoter. In NB
tissues, miR-584-5p was under-expressed and inversely correlated with MMP-14 expression, and was an
independent prognostic factor for favorable outcome of patients. miR-584-5p precursor attenuated the expres-
sion ofMMP-14 in a Dicer-dependentmanner, resulting in decreased levels of vascular endothelial growth factor,
in cultured NB cell lines. In addition, miR-584-5p suppressed the promoter activity ofMMP-14, and mutation of
miR-584-5p binding site abolished these effects. Mechanistically, miR-584-5p recruited Argonaute 2 to facilitate
the enrichment of enhancer of zeste homolog 2, histone H3 lysine 27 trimethylation, and histone H3 lysine 9
dimethylation onMMP-14 promoter in NB cells, which was abolished by repressing the miR-584-5p-promoter
interaction. Gain- and loss-of-function studies demonstrated that miR-584-5p suppressed the growth, invasion,
metastasis, and angiogenesis of NB cells in vitro and in vivo. Moreover, restoration ofMMP-14 expression rescued
the NB cells from changes in these biological features. Taken together, these results indicate that promoter-
targetingmiR-584-5p exerts tumor suppressive functions in NB through repressing the transcription ofMMP-14.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Neuroblastoma (NB), the most common extracranial solid tumor in
childhood, accounts for 15% of all pediatric cancer deaths [1]. For
patients with high-risk NB, despite the application of intensiﬁed thera-
peutic modalities, such as surgery, chemoradiotherapy, stem cell trans-
plantation, and immunotherapy, the prognosis still remains dismal [1].
Better elucidating the mechanisms underlying the tumorigenesis and
aggressiveness of NB is needed for improving its therapeutic efﬁciency.ology, Union Hospital, Tongji
nology, Wuhan 430022, Hubei
Surgery, Union Hospital, Tongji
nology, Wuhan 430022, Hubei
s_tong@hotmail.com (Q. Tong).MicroRNAs (miRNAs) are a class of small non-coding RNAs, ranging
from 22 to 25 nucleotides in length [2]. It has been established that
miRNAs are able to control gene expression at the post-transcriptional
level by interacting with targets, usually in the 3′-untranslated region
(3′-UTR) [3]. Previous studies have shown that many miRNAs regulate
various biological processes of NB, including cell differentiation, prolif-
eration, apoptosis, and angiogenesis [3,4], suggesting the important
roles of miRNAs in the progression of NB.
It is well known that extracellular matrix (ECM) is a barrier to pre-
vent the tumor cells from invasion and metastasis. Matrix metallopro-
teinase 14 (MMP-14), a membrane-anchored MMP, is able to directly
degrade various ECM components, including type I, II, and III collagens,
gelatin, ﬁbronectin, vitronectin, tenascin, entactin, and laminin-1 [5],
and plays an important role in tumor invasion and metastasis by facili-
tating the tumor cells to remodel and penetrate the ECM [5,6]. In addi-
tion, MMP-14 promotes tumor growth and angiogenesis through
facilitating the transcription of vascular endothelial growth factor
1744 X. Xiang et al. / Biochimica et Biophysica Acta 1852 (2015) 1743–1754(VEGF) via activating the Src-tyrosine kinase pathway and regulating
the localization of vascular endothelial growth factor receptor 2 [7–9].
Previous studies have demonstrated that miR-10b induces the invasion
of glioma cells by modulating MMP-14 expression via the direct target
homeobox D10 [10], and miR-9 targets the 3′-UTR of MMP-14 to
suppress its expression in NB cells [11], suggesting the crucial roles of
miRNAs in regulating the MMP-14 expression.
In recent years, deep sequencing has revealed the existence of nucle-
ar miRNAs within many types of human cell lines [12–14]. For the
majority of miRNAs, equal proportions are typically identiﬁed in
both the cytoplasm and nucleus, implying their possible nuclear roles
[12–14]. In addition, there are putative target sites within the promoter
regions of many human genes [15]. Subsequent evidence shows that
certain endogenous promoter-targeting miRNAs are able to regulate
gene transcription in human cells [16–19]. However, the roles of
miRNAs in regulating the transcription of MMP-14 in NB still remain
largely unknown. In the current study, we demonstrated, for the ﬁrst
time, that miR-584-5p was down-regulated and inversely correlated
withMMP-14 expression in clinical NB specimens, and directly targeted
the MMP-14 promoter to suppress its transcription via inducing chro-
matin remodeling, thus inhibiting the growth, invasion, metastasis,
and angiogenesis of NB cells in vitro and in vivo, suggesting the tumor
suppressive roles of miR-584-5p in the progression of NB.
2. Materials and methods
2.1. Patient tissue samples
Approval to conduct this study was obtained from the Institutional
Review Board of Tongji Medical College (approval number: 2011-
S085). Fresh tumor specimens from 42 well-established primary NB
cases were collected, and stored at−80 °C until use. The pathological
diagnosis of NB was conﬁrmed by at least two pathologists. Based on
the Shimada classiﬁcation system, including the mitosis karyorrhexis
index, degree of neuroblastic differentiation and stromal maturation,
and patient's age, 18 patients were classiﬁed as having favorable histol-
ogy and 24 as having unfavorable histology. According to the interna-
tional neuroblastoma staging system (INSS), 4 patients were classiﬁed
as stage 1, 10 as stage 2, 14 as stage 3, 6 as stage 4, and 8 as stage 4S.
Total RNA of human normal dorsal ganglia, pooling from 21 male/female
Caucasians, was obtained from Clontech (Mountain View, CA).
2.2. Promoter-targeting miRNA prediction and expression detection
The miRNA binding sites within MMP-14 promoter were analyzed
using the algorithm miRWalk [20] and genome-wide Argonaute-
chromosome interaction proﬁling data (GSE40536). Cytoplasmic and
nuclear fractionswere preparedwith the NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Thermo Fisher Scientiﬁc, Inc., Waltham, MA).
The mature miR-584-5p levels in primary tissues and cell lines were
determined using Bulge-Loop™miRNAs qPCR Primer Set (RiboBio Co.,
Ltd, Guangzhou, China). After cDNA was synthesized with a miRNA-
speciﬁc stem-loop primer, the quantitative PCR was performed with
the speciﬁc primers (Supplementary Table S1). The miRNA levels
were normalized as to those of U6 snRNA. The degree of miRNA levels
in tumor specimens was classiﬁed into “high expression” and “low
expression” groups, in which the miRNA levels were higher or lower
than the median expression of all samples, respectively.
2.3. Western blot
Cellular protein was extracted with 1× cell lysis buffer (Promega,
Madison, WI). Western blot was performed as previously described
[21–24], with antibodies speciﬁc for MMP-14 (Abcam Inc., Cambridge,
MA), VEGF (Santa Cruz Biotechnology, Santa Cruz, CA), Argonaute 1
(AGO1), Argonaute 2 (AGO2), Argonaute 3 (AGO3), Argonaute 4(AGO4), Dicer (Cell Signaling Technology, Inc., Danvers, MA), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Santa Cruz
Biotechnology).2.4. Real-time quantitative RT-PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen Inc., Valencia,
CA). The reverse transcription reactions were conducted with
Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN).
Real-time PCR was performed with SYBR Green PCR Master Mix (Ap-
plied Biosystems, Foster City, CA) and primers indicated in Supplemen-
tary Table S1. The transcript levels were analyzed by 2−ΔΔCt method.2.5. Cell culture and transfection
Human NB cell lines SK-N-SH (HTB-11), SK-N-AS (CRL-2137), SH-
SY5Y (CRL-2266), and SK-N-BE(2) (CRL-2271), and the human endo-
thelial cell line HUVEC (CRL-1730) were purchased from American
Type Culture Collection (Rockville, MD). Cell lines were authenticated
by the provider, used within 6 months after resuscitation of frozen
aliquots, and grown in RPMI1640 medium (Life Technologies, Inc., Gai-
thersburg, MD) supplemented with 10% fetal bovine serum (Life Tech-
nologies, Inc.), penicillin (100 U/mL), and streptomycin (100 μg/mL).
Cells were maintained at 37 °C in a humidiﬁed atmosphere of 5% CO2
and applied for transfection or treatment with 5-aza-2′-deoxycytidine
(5-Aza-CdR; Sigma, St. Louis, MO) as indicated. Anti-miR-584-5p or
negative control inhibitors (RiboBio Co., Ltd) were transfected into
conﬂuent cells with Lipofectamine 2000 (Life Technologies, Inc.).2.6. Pre-miRNA construct and stable transfection
According to the pre-miR-584-5p (5′-TTATGGTTTGCCTGGGACTG
AG-3′) sequence documented in the miRNA Registry database [25],
oligonucleotides encoding the precursor of miR-584-5p (Supplementa-
ry Table S2) were subcloned into pcDNA3.1(−) (Genechem Co., Ltd,
Shanghai, China). The plasmids pcDNA3.1 and pcDNA3.1-miR-584-5p
were transfected into tumor cells, and stable cell lines were screened
by administration of neomycin (Invitrogen, Carlsbad, CA).2.7. Luciferase reporter assay
HumanMMP-14 promoter luciferase reporter construct was kindly
provided by Dr. Jouko Lohi (University of Helsinki, Finland) [26], and
MMP-14 and VEGF 3′-UTR luciferase reporter vectors were previously
described [11]. Mutation of miR-584-5p binding site was established
with GeneTailor™ Site-Directed Mutagenesis System (Invitrogen) and
PCR primers (Supplementary Table S2). Dual-luciferase assay was
performed as previously described [11,21,27–30]. For promoter and
3′-UTR activity, the luciferase signal was normalized by ﬁreﬂy/Renilla
and Renilla/ﬁreﬂy ratio, respectively.2.8. Nuclear run-on assay
Nuclear run-on assay was performed based on the incorporation of
biotin-16-uridine-5′-triphosphate (biotin-16-UTP) into nascent tran-
scripts as previously described [27]. Brieﬂy, nuclei of 5 × 106 tumor
cells were isolated and consequently incubated in reaction buffer
containing rNTPs and biotin-16-UTP (Roche, Indianapolis, IN) at 30 °C
for 45 min. The reaction was stopped by adding RNase-free DNase I,
and the nuclei were lysed and treated with proteinase K. Total RNA
was extracted using Trizol (Invitrogen), and biotinylated nascent RNA
was puriﬁed using agarose-conjugated streptavidin beads (Invitrogen)
for real-time quantitative RT-PCR assay.
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HumanMMP-14 expression vectorwas previously described [11]. To
restore miRNA-induced down-regulation of MMP-14, stable cell lines
were transfected with pcDNA3.1-MMP14. The 21-nucleotide small in-
terfering RNAs (siRNAs) targeting the encoding regions of MMP-14
[11], AGO1 [27], AGO2 [27], AGO3, AGO4, and Dicer were chemically
synthesized (RiboBio Co., Ltd) and transfected with Genesilencer
Transfection Reagent (Genlantis, San Diego, CA). The scramble siRNA
(si-Scb) was applied as a control (Supplementary Table S2).
2.10. Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was performed
according to the instructions of EZ-ChIP kit (Upstate Biotechnology,
Temecula, CA) [27–31] with antibodies for AGO1, AGO2, zeste homolog
2 (EZH2), histoneH3 lysine 27 trimethylation (H3K27me3), and histone
H3 lysine 9 dimethylation (H3K9me2; Upstate Biotechnology). Lysates
were treated with either RNase H (10 U) or RNase A (20 μg) prior to
immunoprecipitation. DNA was sonicated into fragments of an average
size of 200 bp. Real-time quantitative PCR (qPCR) was performed with
SYBR Green PCR Master Mix and primer sets targeting the binding site
of miR-584-5p within MMP-14 promoter (Supplementary Table S1).
The amount of immunoprecipitated DNA was calculated in reference
to a standard curve and normalized to input DNA.
2.11. Cell viability assay
Tumor cells were cultured in 96-well plates at 5 × 103 cells per well.
Cell viability was monitored by the 2-(4,5-dimethyltriazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT, Sigma) colorimetric assay [27].
All experiments were done with 6–8 wells per group and repeated at
least three times.
2.12. Scratch migration assay
Tumor cells were cultured in 24-well plates and scraped with the
ﬁne end of 1-mL pipette tips (time 0 h). Plates were washed twice
with phosphate buffered saline to remove detached cells, and incubated
with complete growthmedium. Cell migrationwas photographed using
10 high-power ﬁelds, at 0, 24 h post-induction of injury. Remodeling
was determined as previously described [11,21,28,31].
2.13. Cell invasion assay
Matrigel invasion assay was performed using membranes coated
with Matrigel matrix (BD Science, Sparks, MD). Homogeneous single
cell suspensions (1 × 105 cells/well) were added to the upper chambers
and allowed to invade for 24 h at 37 °C in a CO2 incubator. Invaded cells
were stained with 0.1% crystal violet for 10 min at room temperature.
Quantiﬁcation of invaded cells was performed as previously described
[11,21–23,31,32].
2.14. Tube formation assay
Fifty microliters of growth factor-reduced matrigel were polymer-
ized on 96-well plates. HUVECswere serum starved in RPMI1640medi-
um for 24 h, suspended in RPMI1640 medium preconditioned with
tumor cells, added to matrigel-coated wells at the density of 5 × 104
cells/well, and incubated at 37 °C for 18 h. Quantiﬁcation of anti-
angiogenic activity was calculated as previously described [21,22,28].
2.15. In vivo growth and metastasis assay
All animal experiments were approved by the Animal Care Commit-
tee of Tongji Medical College (approval number: Y20080290). Forin vivo tumor growth studies, 2-month-old male nude mice (n = 5
per group) were injected subcutaneously in the upper back with
1 × 106 tumor cells stably transfected with empty or miR-584-5p pre-
cursor vectors. One month later, mice were sacriﬁced and examined
for tumor weight and gene expression. The experimental metastasis
(0.4 × 106 tumor cells per mouse, n = 5 per group) studies were per-
formed with 2-month-old male nude mice as previously described
[11,21,28].
2.16. Immunohistochemistry
Immunohistochemical staining was performed as previously
described [11,21,28,33], with antibodies speciﬁc for MMP-14 (Abcam
Inc.; Santa Cruz Biotechnology; 1:200 dilution), VEGF and CD31 (Santa
Cruz Biotechnology; 1:200 dilutions). The negative controls included
parallel sections treated without primary antibody or with rabbit
polyclonal IgG (Abcam Inc.). The degree of immunoreactivity was
determined according to the percentage of positive tumor cells.
2.17. Statistical analysis
Unless otherwise stated, all data were shown as mean ± standard
error of the mean (SEM). The χ2 analysis and Fisher exact probability
analysis were applied to compare the gene expression in tumor tissues
with different clinicopathological features. Pearson's coefﬁcient correla-
tion was applied for analyzing the relationship among gene expression.
The log-rank test and Cox regressionmodelwere used to assess survival
difference and hazard ratios. Difference of tumor cells was determined
by t test or analysis of variance (ANOVA).
3. Results
3.1. miR-584-5p is under-expressed and inversely correlated with MMP-14
levels in NB tissues and cell lines
In previous studies, we have demonstrated the high expression of
MMP-14 in primary NB [11]. To further investigate the hypothesis that
the transcription ofMMP-14may be regulated by miRNA in NB, we an-
alyzed the miRWalk database [20] and AGO-chromosome interaction
proﬁling data (GSE40536). Enrichment of AGO1 and AGO2 was noted
at bases −708/−106 relative to the transcription start site (TSS) of
MMP-14. Within this region, there were potential binding sites of miR-
17, miR-1226, and miR-584-5p with high complementarity, locating at
bases−718/−708,−518/−508, and−167/−150 upstreamMMP-14
TSS, respectively (Fig. 1A). Dual-luciferase assay indicated that transfec-
tion of miRNAmimic and inhibitor of miR-584-5p, but not of miR-17 or
miR-1226, resulted in altered promoter activity ofMMP-14 in cultured
NB cell lines (Fig. 1B). Mining the publicly available clinical tumor
expression datasets [R2: microarray analysis and visualization platform
(http://r2.amc.nl)] revealed that the expression of SH3 domain and
tetratricopeptide repeats 2 (SH3TC2), the host gene of miR-584-5p
[34], was down-regulated in specimens from 498 well-established NB
cases than that in normal dorsal ganglia (P b 0.0001, Supplementary
Fig. S1A). In addition, the SH3TC2 levels were inversely correlated
with the aggressiveness and stroma maturation of neuroblastic tumors
(P = 0.0405 and P = 0.0095, Supplementary Fig. S1A) and advanced
INSS stages (P b 0.0001, Supplementary Fig. S1B). Lower SH3TC2 levels
were observed in NB tissues with MYCN ampliﬁcation (P b 0.0001,
Supplementary Fig. S1B) or high risk (P b 0.0001, Supplementary
Fig. S1B). There was a negative correlation between SH3TC2 andMYCN
transcript levels in NB tissues (correlation coefﬁcient R = −0.362,
P b 0.0001, Supplementary Fig. S1C) and cell lines (R = −0.59, P =
0.0024, Supplementary Fig. S1D). Patients with low SH3TC2 levels had
lower survival probability than those with high expression (P =
1.6 × 10−17, Supplementary Fig. S1E). To further investigate the
expression of miR-584-5p, real-time quantitative RT-PCR was applied
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Fig. 1.miR-584-5p is under-expressed and inversely correlatedwithMMP-14 levels inNB tissues and cell lines. (A) Scheme of potential binding sites ofmiR-17,miR-1226, andmiR-584-5p
within theMMP-14 promoter, locating at bases−718/−708,−518/−508, and−167/−150 relative to transcription start site (TSS). (B) Dual-luciferase assay showing theMMP-14 pro-
moter activity in cultured SH-SY5Y, SK-N-BE(2), and SK-N-SH cells transfected with control mimic (mock), negative control inhibitor (anti-NC), and mimic or inhibitor (100 nmol/L) of
miR-584-5p, miR-17 or miR-1226. (C) Real-time quantitative RT-PCR showing themiR-584-5p levels in normal dorsal ganglia (DG, n= 21), NB tissues (n= 42), and NB cell lines [SK-N-
SH, SK-N-AS, SH-SY5Y, and SK-N-BE(2)]. (D) Real-time quantitative RT-PCR showing the inverse correlation between miR-584-5p expression andMMP-14 transcript levels in NB tissues
(n = 42). (E) Real-time quantitative RT-PCR revealing the miR-584-5p levels in NB tissues with well (WD) or poor differentiation (PD). (F) Real-time quantitative RT-PCR showing the
miR-584-5p levels in NB tissues with early (1 + 2) or advanced (3 + 4 + 4S) INSS stages. (G) Real-time quantitative RT-PCR indicating the miR-584-5p levels inMYCN-ampliﬁed and
MYCN-non-ampliﬁed NB tissues. (H) Kaplan–Meier survival plots of 42 well-deﬁned NB cases with high or low expression of miR-584-5p. *P b 0.01 vs. mock, anti-NC, or DG.
1746 X. Xiang et al. / Biochimica et Biophysica Acta 1852 (2015) 1743–1754to measure the mature miR-584-5p levels in 42 NB specimens, normal
dorsal ganglia, and cultured SK-N-SH, SK-N-AS, SH-SY5Y, and SK-N-
BE(2) cell lines. As shown in Fig. 1C, mature miR-584-5p was down-
regulated in NB tissues and cell lines compared with normal dorsal
ganglia. The miR-584-5p expression was inversely correlated with
MMP-14 transcript levels (R =−0.576, P b 0.0001, Fig. 1D) and posi-
tively correlated with SH3TC2 levels in NB tissues (R = 0.57,
P b 0.0001, Supplementary Fig. S1F). Lower miR-584-5p levels were
observed in NB tissues with poor differentiation (P= 0.0092, Fig. 1E),
advanced INSS stage (P = 0.0052, Fig. 1F), or MYCN ampliﬁcation
(P = 0.0215, Fig. 1G). Patients with low miR-584-5p (P b 0.001) or
high MMP-14 (P = 0.037) expression had lower survival probability
(Fig. 1H and Supplementary Fig. S1E), and miR-584-5p (hazard
ratio = 2.235, P = 0.036) and MMP-14 (hazard ratio = 2.412, P =
0.012) were independent prognostic factors for the outcome of NB
patients (Supplementary Table S3). Moreover, down-regulation of
miR-584-5p was also noted in glioma tissues (P b 0.0001), and miR-
584-5p levels were positively and inversely correlated with SH3TC2
(R = 0.884, P = 0.0193) or MMP-14 (R = −0.873, P = 0.0231)expression, respectively (Supplementary Fig. S1G). These results indi-
cated that miR-584-5p was under-expressed and inversely correlated
withMMP-14 transcript levels in NB tissues and cell lines.
3.2. miR-584-5p represses the transcription of MMP-14 in NB cells
We next performed the miRNA over-expression and knockdown
experiments to investigate the direct effects of miR-584-5p on MMP-
14 expression in NB cell lines. Since above evidence showed the varied
miR-584-5p levels in NB cell lines, we chose the SH-SY5Y and SK-N-
BE(2) cells for gain-of-function studies, and applied the SH-SY5Y and
SK-N-SH cells for loss-of-function experiments. Real-time quantitative
RT-PCR, nuclear run-on, and western blot demonstrated that stable
transfection of miR-584-5p precursor into SH-SY5Y and SK-N-
BE(2) cells resulted in increase of cytoplasmic and nuclear miR-584-
5p levels (Fig. 2A), and decreased nascent transcript and protein levels
of MMP-14 in NB cells (Fig. 2B, C, and D), when compared to those sta-
bly transfectedwith empty vector (mock). As theMMP-14 downstream
target gene in NB [11], VEGF was also signiﬁcantly down-regulated in
A Mock miR-
584
-
5p
MMP-14
GAPDH
D
VEGF
MMP-14
GAPDH
VEGF
SH
-
SY
5Y
SK
-N
-B
E(
2)01
2
3
4
5
6
7
8
Mo
ck
m
iR-
58
4-5
p
R
el
at
iv
e 
m
iR
-
58
4-
5p
 
le
v
el
s
(n
or
m
al
iz
ed
 to
 U
6)
Cytoplasm
Nuclear
SH
-
SY
5Y
0
1
2
3
4
5
6
7
8
9
Mo
ck
m
iR-
58
4-5
p
R
el
at
iv
e 
m
iR
-
58
4-
5p
 
le
ve
ls
(n
o
rm
al
iz
ed
 to
 
U
6)
Cytoplasm
Nuclear
SK
-N
-B
E(
2)
0
0.2
0.4
0.6
0.8
1
1.2
Mo
ck
m
iR-
58
4-5
p
R
e
la
tiv
e
 
M
M
P-
14
 e
xp
re
s
s
io
n
(n
o
rm
a
liz
e
d 
to
 
G
A
PD
H
) SH-SY5Y
SK-N-BE(2)
0
0.2
0.4
0.6
0.8
1
1.2
Mo
ck
m
iR-
58
4-5
p
Re
la
tiv
e 
VE
G
F 
ex
pr
es
si
o
n
(n
o
rm
al
iz
ed
 
to
 
G
AP
DH
) SH-SY5Y
SK-N-BE(2)
B
SH
-
SY
5Y
0
0.2
0.4
0.6
0.8
1
1.2
Mo
ck
m
iR-
58
4-5
p
R
el
at
iv
e 
tr
an
sc
rip
t l
ev
el
s
(b
y 
qR
T-
PC
R
) MMP-14
VEGF
SK
-N
-B
E(
2)
0
0.2
0.4
0.6
0.8
1
1.2
Mo
ck
m
iR-
58
4-5
p
R
el
a
tiv
e
 tr
a
n
s
c
rip
t l
e
v
e
ls
(by
 
qR
T-
PC
R
) MMP-14
VEGF
E
MMP-14
GAPDH
H
VEGF
MMP-14
GAPDH
VEGF
SH
-
SY
5Y
SK
-N
-S
H
SH
-
SY
5Y
SK
-N
-S
H
0
1
2
3
An
ti-N
C
An
ti-m
iR-
58
4-5
p
R
e
la
tiv
e
 M
M
P-
14
 e
xp
re
s
s
io
n
(no
rm
a
liz
e
d 
to
 
GA
PD
H
) SH-SY5Y
SK-N-SH
0
1
2
3
An
ti-N
C
An
ti-m
iR-
58
4-5
p
Re
la
tiv
e 
VE
G
F 
ex
pr
es
si
o
n
(n
or
m
al
iz
ed
 to
 G
A
PD
H
) SH-SY5Y
SK-N-SH
F
SH
-
SY
5Y
0
1
2
3
4
5
6
An
ti-N
C
An
ti-m
iR-
58
4-5
p
R
e
la
tiv
e
 
tr
a
n
s
c
rip
t l
ev
e
ls
(by
 
qR
T-
PC
R
) MMP-14
VEGF
SK
-N
-S
H
0
1
2
3
4
5
6
An
ti-N
C
An
ti-m
iR-
58
4-5
p
R
el
a
tiv
e
 
tr
a
n
s
c
rip
t l
e
v
e
ls
(by
 
qR
T-
PC
R
)
MMP-14
VEGF
An
ti-N
C
0
0.2
0.4
0.6
0.8
1
1.2
An
ti-N
C
An
ti-m
iR-
58
4-5
p
R
el
a
tiv
e
 
m
iR
-5
84
-
5p
 
le
v
e
ls
(no
rm
a
liz
e
d 
to
 
U6
)
Cytoplasm
Nuclear
0
0.2
0.4
0.6
0.8
1
1.2
An
ti-N
C
An
ti-m
iR-
58
4-5
p
Re
la
tiv
e 
m
iR
-
58
4-
5p
 
le
ve
ls
(n
o
rm
al
iz
ed
 to
 
U6
)
Cytoplasm
Nuclear
An
ti-m
iR-
58
4-5
p
*
*
*
*
** **
* *
* *
* *
* *
** **
*
*
*
*
C
SH
-
SY
5Y
0
0.2
0.4
0.6
0.8
1
1.2
Mo
ck
m
iR-
58
4-5
p
Re
la
tiv
e
 M
M
P-
14
 tr
a
n
s
c
rip
t
le
v
e
ls
 (b
y 
nu
c
le
a
r 
ru
n
-
o
n
)
SK
-N
-B
E(
2)
G
SH
-
SY
5Y
SK
-N
-S
H
*
0
0.2
0.4
0.6
0.8
1
1.2
Mo
ck
m
iR-
58
4-5
p
Re
la
tiv
e
 
M
M
P-
14
 
tr
a
n
s
c
rip
t
le
v
e
ls
 
(by
 
n
u
c
le
a
r 
ru
n
-
o
n
)
*
0
2
4
6
8
An
ti-N
C
An
ti-m
iR-
58
4-5
p
R
el
at
iv
e 
M
M
P-
14
 
tr
an
sc
ri
pt
le
ve
ls
 
(b
y 
nu
cl
ea
r 
ru
n
-
o
n
)
*
0
2
4
6
8
An
ti-N
C
An
ti-m
iR-
58
4-5
p
R
el
at
iv
e 
M
M
P-
14
 tr
an
sc
ri
pt
le
v
el
s 
(b
y 
n
u
cl
ea
r 
ru
n
-
o
n
)
*
Fig. 2.miR-584-5p represses the transcription ofMMP-14 inNB cells. (A) Real-time quantitative RT-PCR showing themiR-584-5p levels in SH-SY5Y and SK-N-BE(2) cells stably transfected
with empty vector (mock) or miR-584-5p precursor. (B and C) Real-time quantitative RT-PCR and nuclear run-on assays showing the transcript levels ofMMP-14 and VEGF in SH-SY5Y
and SK-N-BE(2) cells stably transfectedwith mock ormiR-584-5p precursor. (D)Western blot assay indicating the protein levels of MMP-14 and VEGF in NB cells stably transfectedwith
mock or miR-584-5p precursor. (E) Real-time quantitative RT-PCR showing the miR-584-5p levels in SH-SY5Y and SK-N-SH cells transfected with negative control inhibitor (anti-NC,
100 nmol/L) or anti-miR-584-5p inhibitor (100 nmol/L). (F and G) Real-time quantitative RT-PCR and nuclear run-on assays showing the MMP-14 and VEGF transcript levels in SH-
SY5Y and SK-N-SH cells transfected with anti-NC (100 nmol/L) or anti-miR-584-5p inhibitor (100 nmol/L). (H) Western blot indicating the protein levels of MMP-14 and VEGF in NB
cells transfected with anti-NC (100 nmol/L) or anti-miR-584-5p inhibitor (100 nmol/L). *P b 0.01 vs. mock or anti-NC.
1747X. Xiang et al. / Biochimica et Biophysica Acta 1852 (2015) 1743–1754miR-584-5p over-expressing NB cells (Fig. 2B and D). In addition,
knockdown of Dicer, the ribonuclease that cleaves themiRNA precursor
for the biogenesis of mature miRNA [35], increased the MMP-14 levels
and abolished the effects of miR-584-5p precursor on the MMP-14
expression in NB cells (Supplementary Fig. S2A and B), which was in
linewith the inverse correlation betweenDicer andMMP-14 expression
in public NB datasets (Supplementary Fig. S2C). Meanwhile, transfec-
tion of anti-miR-584-5p inhibitor into SH-SY5Y and SK-N-SH cells
obviously down-regulated the cytoplasmic and nuclear expression
of miR-584-5p (Fig. 2E), and up-regulated the transcript and protein
levels of MMP-14 and VEGF (Fig. 2F, G, and H), when compared with
those transfected with negative control (anti-NC) inhibitor. Since
analysis of miRWalk database revealed no potential binding site of
miR-584-5p within the VEGF promoter, we ruled out the possibility
that miR-584-5p may directly regulate the transcription of VEGF. Inaddition, over-expression or knockdown of miR-584-5p in NB cells
did not affect the 3′-UTR luciferase activity ofMMP-14 or VEGF (Sup-
plementary Fig. S3), indicating no involvement of post-transcription
regulation by miR-584-5p. Overall, these results demonstrated that
miR-584-5p considerably repressed the transcription of MMP-14 in
NB cells.
3.3. miR-584-5p targets the binding site and recruits AGO2 on MMP-14
promoter
To determine whether or not miR-584-5p could repress MMP-14
expression by targeting its binding site, we performed the dual-
luciferase assay withMMP-14 promoter-luciferase reporter or a mutant
of miR-584-5p recognition site (Fig. 3A). The ﬁreﬂy luciferase activity
normalized to that of Renillawas signiﬁcantly reduced in SH-SY5Y and
Fig. 3.miR-584-5p targets the binding site and recruited AGO2 onMMP-14 promoter. (A) Scheme and sequence of intactmiR-584-5p binding site (WT) and its mutation (Mut)within the
MMP-14 promoter-luciferase reporter vector. (B) Dual-luciferase assay showing the activity of MMP-14 promoter reporter and its mutant in SH-SY5Y and SK-N-BE(2) cells stably
transfected with empty vector (mock) or miR-584-5p precursor. (C) Dual-luciferase assay showing the activity ofMMP-14 promoter reporter and its mutant in SH-SY5Y and SK-N-SH
cells transfected with negative control inhibitor (anti-NC, 100 nmol/L) or anti-miR-584-5p inhibitor (100 nmol/L). (D) ChIP and qPCR assay indicating the enrichment of AGO1 and
AGO2 on theMMP-14 promoter in SH-SY5Y and SK-N-BE(2) cells stably transfected with mock or miR-584-5p precursor. *P b 0.01 vs. mock, anti-NC, or IgG.
1748 X. Xiang et al. / Biochimica et Biophysica Acta 1852 (2015) 1743–1754SK-N-BE(2) cells stably transfected with miR-584-5p precursor
(Fig. 3B), than those stably transfected with empty vector (mock), and
these effects were abolished by mutation of miR-584-5p binding site
within MMP-14 promoter (Fig. 3B). In addition, transfection of anti-
miR-584-5p inhibitor increased the luciferase activity in SH-SY5Y and
SK-N-SH cells (Fig. 3C), while mutation of miR-584-5p recognition site
abolished these effects (Fig. 3C). ChIP and real-time qPCR were next
applied to measure the enrichment of AGO1 and AGO2, main effectors
involved in miRNA-induced transcriptional repression [17,36], onMMP-14 promoter. As shown in Fig. 3D, enrichment of AGO2, but
not of AGO1, was observed around the binding site of miR-584-5p
(−326/−130 bp) in SH-SY5Y and SK-N-BE(2) cells. As controls, no
MMP-14 promoter regions were immunoprecipitated with unspeciﬁc
antibody (isotype IgG) or detected by qPCR with primer set (−122/
+69 bp) distal to the binding site of miR-584-5p (Fig. 3D). In addition,
stable over-expression or knockdown of miR-584-5p increased and
decreased the binding of AGO2 on MMP-14 promoter, respectively
(Fig. 3D and Supplementary Fig. S4). These results indicated that miR-
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Fig. 4.miR-584-5p induces chromatin remodeling atMMP-14 promoter in anAGO2-dependentmanner inNB cells. (A and B)Western blot and real-time quantitative RT-PCR assays showing
the expression of AGO1, AGO2, andMMP-14 in SH-SY5Y and SK-N-BE(2) cells transfectedwith empty vector (mock),miR-584-5p precursor, scramble siRNA (si-Scb), si-AGO1 (100 nmol/L),
or si-AGO2 (100 nmol/L). (C)Nuclear run-on assay indicating the nascentMMP-14 transcription inNB cells transfectedwithmock,miR-584-5p precursor, si-Scb, si-AGO1 (100nmol/L), or si-
AGO2 (100 nmol/L). (D) ChIP and qPCR assay showing the binding of EZH2, H3K27me3, and H3K9me2 onMMP-14 promoter in NB cells stably transfected with mock or miR-584-5p pre-
cursor, and those co-transfected with si-Scb or si-AGO2 (100 nmol/L). (E) ChIP and qPCR assay showing the enrichment of AGO2, EZH2, H3K27me3, and H3K9me2 onMMP-14 promoter in
SH-SY5Y and SK-N-BE(2) stably transfected with mock or miR-584-5p, and those treated with RNase H or RNase A. *P b 0.01 vs. mock + si-Scb or mock.
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1751X. Xiang et al. / Biochimica et Biophysica Acta 1852 (2015) 1743–1754584-5p targeted the binding site and recruited AGO2 on MMP-14
promoter in NB cells.
3.4. miR-584-5p induces chromatin remodeling at MMP-14 promoter in an
AGO2-dependent manner in NB cells
To further explore the potential roles of AGO inmiR-584-5p-induced
transcriptional repression of MMP-14, siRNAs targeting AGO1, AGO2,
AGO3, and AGO4 were transfected into NB cells stably transfected with
empty vector (mock) or miR-584-5p precursor, respectively. Western
blot, real-timequantitative RT-PCR, and nuclear run-on assays indicated
that knockdown of AGO2, but not of AGO1, AGO3, or AGO4, abolished
the miR-584-5p-induced transcriptional repression of MMP-14 in SH-
SY5Y and SK-N-BE(2) cells (Fig. 4A, B, C, Supplementary Fig. S2D, and
E). In addition, the inverse correlation between AGO2 and MMP-14 ex-
pression was noted in public NB dataset (Supplementary Fig. S2F).
Meanwhile, administration of DNA methyltransferase inhibitor 5-Aza-
CdR resulted in no signiﬁcant changes in MMP-14 transcript levels in
miR-584-5p over-expressing NB cells (Supplementary Fig. S5). Instead,
ChIP and qPCR assay indicated the increased binding of EZH2,
H3K27me3, and H3K9me2 on MMP-14 promoter in NB cells stably
transfected with miR-584-5p precursor (Fig. 4D), which was abolished
by knockdown of AGO2 (Fig. 4D). To explore whether miR-584-5p in-
teracts directly with MMP-14 promoter, lysates from miR-584-5p
over-expressing NB cells were pretreated with RNase H or RNase A. As
shown in Fig. 4E, RNase H treatment, but not RNase A treatment,
abolished the miR-584-5p-induced enrichment of AGO2, EZH2,
H3K27me3, and H3K9me2 on MMP-14 promoter in NB cells (Fig. 4E),
indicating a direct interaction between miR-584-5p and MMP-14
promoter. These data suggested that miR-584-5p induced chromatin
remodeling at the MMP-14 promoter in an AGO2-dependent manner
in NB cells.
3.5. miR-584-5p suppresses the growth, migration, invasion, and angiogen-
esis of NB cells through down-regulating MMP-14 in vitro
Based on the promoting roles of MMP-14 in the growth, migration,
and invasion of tumor cells [11,37], we further investigated the effects
of miR-584-5p and MMP-14 restoration on cultured NB cells. As
shown in Fig. 5A, transfection of MMP-14 rescued the miR-584-5p-
induced down-regulation of MMP-14. In MTT colorimetric assay, stable
transfection of miR-584-5p precursor into NB cells decreased the cell
viability, than those stably transfected with empty vector (mock;
Supplementary Fig. S6A). In scratch migration assay, miR-584-5p
over-expression attenuated the migration capability of SH-SY5Y and
SK-N-BE(2) cells (Fig. 5B and Supplementary Fig. S6B). Transwell
analysis revealed the impaired invasion capacity of NB cells stably
transfected with miR-584-5p precursor, than that in mock cells
(Fig. 5C). The tube formation of endothelial cells was suppressed by
treatment with the medium preconditioned by stable transfection of
NB cells with miR-584-5p precursor (Fig. 5D). In addition, transfection
of MMP-14 prevented the SH-SY5Y and SK-N-BE(2) cells from their
decrease in growth, migration, invasion, and angiogenesis induced by
stable over-expression of miR-584-5p (Fig. 5B, C, D, and Supplementary
Fig. S6). On the other hand, transfection of anti-miR-584-5p inhibitor
enhanced the MMP-14 expression (Fig. 5E), and increased the cell via-
bility (Supplementary Fig. S6C), migration (Fig. 5F and SupplementaryFig. 5.miR-584-5p suppresses the migration, invasion, and angiogenesis of NB cells in vitro. (A
vector (mock), miR-584-5p precursor, negative control inhibitor (anti-NC, 100 nmol/L), or anti-
(100 nmol/L). (B and F) Quantiﬁcation of scratchmigration assay showing themigration of NB c
5p inhibitor (100 nmol/L), and those co-transfected withMMP-14 or si-MMP-14 (100 nmol/L
showing the invasion capability of NB cells transfected with mock, miR-584-5p precursor, ant
withMMP-14 or si-MMP-14 (100 nmol/L). (D and H) Representation (top) and quantiﬁcation (
with mock, miR-584-5p precursor, anti-NC (100 nmol/L), or anti-miR-584-5p inhibitor (100 n
mock or anti-NC.Fig. S6D), invasion (Fig. 5G), and angiogenesis (Fig. 5H) of SH-SY5Y
and SK-N-SH cells. In addition, restoration of MMP-14 expression via
transfection of si-MMP-14 rescued the NB cells from their changes in
these biological features induced by knockdown of miR-584-5p
(Fig. 5F, G, H, and Supplementary Fig. S6). Collectively, these results
indicated that miR-584-5p remarkably suppressed the growth, migra-
tion, invasion, and angiogenesis of NB cells through targetingMMP-14
in vitro.
3.6. Over-expression of miR-584-5p attenuates the growth, metastasis, and
angiogenesis of NB cells in vivo
We next investigated the efﬁcacy of miR-584-5p against tumor
growth and metastasis in vivo. Stable transfection of miR-584-5p pre-
cursor into SH-SY5Y cells resulted in decreased growth and tumor
weight of subcutaneous xenograft tumors in athymic nude mice,
when compared to those stably transfected with empty vector (mock)
(Fig. 6A and B). In addition, the miR-584-5p levels within tumors
were increased, and the intratumoral expression of MMP-14 and VEGF
was also reduced by stable transfection of miR-584-5p precursor
(Fig. 6C). Moreover, stable transfection of miR-584-5p precursor result-
ed in decrease in CD31-positive microvessels and mean vessel density
within tumors (Fig. 6C). In experimental metastasis studies, SH-SY5Y
cells stably transfected with miR-584-5p precursor established statisti-
cally fewer lung metastatic colonies than mock group (Fig. 6D). These
results suggested that miR-584-5p inhibited the growth, metastasis,
and angiogenesis of NB cells in vivo.
4. Discussion
Previous studies have shown that exogenous siRNAs with sequence
complementarity to promoter regions induce transcriptional inhibition
in human cells through inﬂuencing the heterochromatin assembly and
promoter methylation [27,38–40], suggesting that endogenous small
RNA-directed transcriptional processes might exist in mammals. Actu-
ally, deep sequencing has revealed a high abundance of endogenous
miRNAs within nucleus [12–14], and in silico target prediction suggests
many potentialmiRNA-promoter interaction sites [15]. Recent evidence
has shown that let-7 physically and functionally interacts with AGO2
and retinoblastoma 1 (RB1) to transcriptionally repress the RB1/E2F-
target genes in senescence, and AGO2 is essential for let-7-directed im-
plementation of silent-state chromatinmodiﬁcation at target promoters
[36]. In addition, miR-10a represses the expression of homeobox D4 at
the transcriptional levels through targeting a homologous promoter
region, and is associated with the presence of AGO1, AGO3, and
promoter-associated non-coding RNAs [17]. Meanwhile, miR-373
functions in trans to activate gene expression of E-cadherin in prostate
cancer cells through recruiting RNA polymerase II at target promoter
[19]. These studies reveal the negative or positive effects of miRNAs
on gene transcription.
MicroRNA-584 (miR-584) is a recently identiﬁedmiRNAwith tumor
suppressive functions. Down-regulation of miR-584 is a pre-requisite
for transforming growth factor beta-mediated migration and motility
in human breast cancer cells [41], and phosphatase and actin regulator
1 is identiﬁed as a downstream target of miR-584 [41]. In renal cell car-
cinoma, miR-584 is down-regulated and functions as a tumor suppres-
sor that directly targets oncogene Rho-associated coiled-coil containingand E) Western blot showing the MMP-14 expression in NB cells transfected with empty
miR-584-5p inhibitor (100 nmol/L), and those co-transfected withMMP-14 or si-MMP-14
ells transfectedwithmock,miR-584-5p precursor, anti-NC (100 nmol/L), or anti-miR-584-
). (C and G) Representation (top) and quantiﬁcation (bottom) of matrigel invasion assay
i-NC (100 nmol/L), or anti-miR-584-5p inhibitor (100 nmol/L), and those co-transfected
bottom) of tube formation assay showing the angiogenic capability of NB cells transfected
mol/L), and those co-transfected withMMP-14 or si-MMP-14 (100 nmol/L). *P b 0.01 vs.
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Fig. 6. Over-expression of miR-584-5p attenuates the growth and metastasis of NB cells in vivo. (A) Tumor growth curve of SH-SY5Y cells (1 × 106) stably transfected with empty vector
(mock) ormiR-584-5p precursor in athymic nudemice (n= 5 for each group), after hypodermic injection for 4 weeks. (B) Representation (top) and quantiﬁcation (bottom) of xenograft
tumors formed by hypodermic injection of SH-SY5Y cells stably transfected with mock or miR-584-5p precursor. (C) Immunohistochemical staining and real-time quantitative RT-PCR
showing the expression ofMMP-14, VEGF, CD31, andmiR-584-5pwithin tumors formed by hypodermic injection of SH-SY5Y cells stably transfectedwithmock ormiR-584-5p precursor.
Scale bars: 100 μm. (D) Representation (top, arrowhead) and quantiﬁcation (bottom) of lungmetastasis after injection of SH-SY5Y cells (0.4 × 106) stably transfected with mock or miR-
584-5p precursor into the tail vein of athymic nude mice (n = 5 for each group). Scale bars: 100 μm. *P b 0.001 vs. mock.
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miR-584 is down-regulated in human glioma, and suppresses the
growth and invasion of glioma cells by targeting pituitary tumor-
transforming 1 interacting protein, implicating the tumor suppressive
roles of miR-584 in human glioma pathogenesis [43]. In this study, we
found that miR-584-5p was down-regulated and inversely correlated
with MMP-14 expression in NB tissues and cell lines. Previous studies
show that SH3TC2, the host gene of miR-584-5p [34], is essential for
the proper myelination and integrity of peripheral nervous system
[44], and SH3TC2 deﬁciency is associatedwith severe hereditary periph-
eral neuropathy [45]. Notably, we also found the down-regulation of
SH3TC2 in NB tissues and cell lines, suggesting the potential roles of
SH3TC2 in the progression of NB. Through an integrative approach to
analyze the public datasets, we identiﬁedmiR-584-5p as a novel regula-
tor of MMP-14 transcription. We demonstrated that miR-584-5p
suppressed the expression of MMP-14 through targeting its promoterand repressing transcription, indicating the tumor suppressive roles of
miR-584-5p in NB. Interestingly, we also noted the inverse correlation
between miR-584-5p and MMP-14 levels in glioma, another common
malignant tumor of the nervous system. Since MMP-14 is elevated
and signiﬁcantly associated with advanced grades of brain glioma, and
serves as an independent prognostic factor for poor overall survival of
glioma patients [46,47], we suspect that down-regulation of miR-584-
5p may also contribute to high MMP-14 expression in glioma, which
warrants further investigation.
HumanMMP-14 gene expression is regulated at the transcriptional
levels [26]. The activity of MMP-14 promoter is dependent on cis-
regulatory elements, and strong MMP-14 transcription is correlated
with hypomethylation and low H3K27me3 levels at promoter region
[48]. Since administration of DNA methyltransferase inhibitor resulted
in no signiﬁcant changes in miR-584-5p-induced transcriptional
repression ofMMP-14 in NB cells,we ruled out the possible involvement
1753X. Xiang et al. / Biochimica et Biophysica Acta 1852 (2015) 1743–1754of aberrant promoter hypermethylation in this process. EZH2, a
histonelysine N-methyltransferase, maintains a repressive chromatin
state by promoting the repressive chromatinmarkH3K27me3 [49]. Pre-
vious studies have shown that during the transcription inhibition, miR-
709 is able to form epigenetic silencing complexes with H3K27me3 at
the promoter of early growth response 2 [50], while miR-320 is
associated with directing EZH2 and H3K27me3 onto the promoter of
RNA polymerase III polypeptide D [18]. In this study, we found that
the recruitment of suppressive epigenetic markers EZH2, H3K27me3,
and H3K9me2 at MMP-14 promoter was increased in miR-584-5p
over-expressing NB cells, indicating that miR-584-5p may induce
epigenetic inactivation by deposition of suppressive chromatin marks
at gene promoter.
Previous studies suggest the dependence of nuclear miRNA on the
recognition site within promoter, in a manner typical of cytoplasmic
miRNA targeting [19,51]. In this study, we found that mutation of
binding site abolished the miR-584-5p-repressed promoter activity of
MMP-14, and treatment with RNase H (speciﬁcally degrades the RNA
present in RNA–DNA hybrid) [16] abolished the miR-584-5p-induced
enrichment of AGO2, EZH2, H3K27me3, and H3K9me2, suggesting a
direct interaction between miR-584-5p and MMP-14 promoter. AGO1,
AGO2, and AGO3 have been previously implicated in miRNA-induced
transcription inhibition through promoting changes in histone covalent
modiﬁcations and DNA methylation [17,52]. In this study, our evidence
indicated that miR-584-5p recruited AGO2 to facilitate the enrichment
of suppressive epigenetic markers at the MMP-14 promoter in NB
cells. In addition, knockdown of AGO2, but not of AGO1, AGO3, or
AGO4, abolished the miR-584-5p-induced transcriptional repression of
MMP-14. We believe that miR-584-5p/AGO2 complexes may bring
in co-repressors such as histone methyltransferases to silence gene
expression, which warrants our further investigation.
5. Conclusions
In summary, we have demonstrated that miR-584-5p is down-
regulated in human NB, and over-expression of miR-584-5p inhibits
the growth, invasion, metastasis, and angiogenesis of NB cells in vitro
and in vivo. Furthermore, miR-584-5p suppresses the transcription of
MMP-14 via the binding site within its promoter in NB cell lines. This
study extends our knowledge about the regulation of MMP-14 at
transcriptional levels by miRNAs, and suggests that miR-584-5p may
be of potential values as a novel therapeutic target for human NB.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.06.002.
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